1. Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses;Collister;J Clin Epidemiol,2021
2. Responder analyses and the assessment of a clinically relevant treatment effect;Snapinn;Trials,2007
3. Consequences of dichotomization;Fedorov;Pharm Stat,2009
4. Responder analyses – a PhRMA position paper;Uryniak;Stat Biopharm Res,2011
5. European Medicines Agency. Guideline on multiplicity Issues in clinical trials. London, United Kingdom: European Medicines Agency; 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-multiplicity-issues-clinical-trials_en.pdf. Accessed: February 10, 2021.